Meta-analysis from 3 publications (n = 390) showed no significant difference in the overall anemia incidence between SYK and/or BTK inhibitors and placebo (RR 0.92; 95%CI: 0.32 – 2.62, p=0.87, I2 = 48%, random-effect model), regardless of the its severity as grade 1 – 2 (RR 1.20; 95%CI: 0.26 – 5.55, p=0.81, I2 = 69%, random-effect model) oor grade ≥3 anemia (RR 0.48; 95%CI: 0.13 – 1.80, p=0.27, I2 = 0%, random-effect model) (Table 3). The gene discussed is BTK; the disease is anemia.